Niagen Bioscience Inc. Common Stock (NAGE)
Stock · NASDAQ · Health Care
$2.49as of 10/16/2026
Price chart
Active signals
NAGE Signal Track Record
How signals performed across all stocks →What NAGE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -3.6% | 44% | October 1, 2026 |
| Bollinger Band Breakdown | 21 | -0.6% | 48% | October 1, 2026 |
| Bollinger Band Breakout | 21 | -0.5% | 48% | April 22, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -1.2% | 40% | January 25, 2024 |
| Any 20-session window (baseline) | -2.8% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NAGE
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolis…
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Employees
- 117
- Website
- www.niagenbioscience.com/
Fundamentals
- 1-day range
- $2.53$2.6
- Market cap
- $240.54M
- P/E (trailing)
- 12.74
- P/E (forward)
- -43.00
- EPS (trailing)
- $0.19
- Dividend yield
- —
- Beta
- 2.07
- Avg. volume
- 557.1K
How Niagen Bioscience Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 4, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Niagen Bioscience Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NAGENiagen Bioscience Inc. Common Stock$2.49▼ 3.49%Market cap $240.54MP/E 12.74$2.51$7.95
- OBIOOrchestra BioMed Holdings Inc. Ordinary Shares$5.45▼ 5.05%Market cap $248.50MP/E —$3.1$6.5
- USNAUSANA Health Sciences Inc. Common Stock$15.54▲ 1.04%Market cap $274.91MP/E 32.28$12.57$23.59
- ACBAurora Cannabis Inc. Common Shares$3.99▼ 2.68%Market cap $184.63MP/E —$3.59$8.75
- MDWDMediWound Ltd. Ordinary Shares$11.85▼ 2.95%Market cap $183.44MP/E —$11.9$20.03
- SNDLSNDL Inc. Common Shares$1.25▲ 3.31%Market cap $312.36MP/E —$1.13$2.57
- FTLFFitLife Brands Inc. Common Stock$8.39▼ 2.21%Market cap $95.88MP/E 12.92$8.5$20.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NAGE Niagen Bioscience Inc. Common Stock | $240.54M | 12.74 | $2.49 | ▼ 3.49% | $2.51$7.95 |
| OBIO Orchestra BioMed Holdings Inc. Ordinary Shares | $248.50M | — | $5.45 | ▼ 5.05% | $3.1$6.5 |
| USNA USANA Health Sciences Inc. Common Stock | $274.91M | 32.28 | $15.54 | ▲ 1.04% | $12.57$23.59 |
| ACB Aurora Cannabis Inc. Common Shares | $184.63M | — | $3.99 | ▼ 2.68% | $3.59$8.75 |
| MDWD MediWound Ltd. Ordinary Shares | $183.44M | — | $11.85 | ▼ 2.95% | $11.9$20.03 |
| SNDL SNDL Inc. Common Shares | $312.36M | — | $1.25 | ▲ 3.31% | $1.13$2.57 |
| FTLF FitLife Brands Inc. Common Stock | $95.88M | 12.92 | $8.39 | ▼ 2.21% | $8.5$20.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)Yahoo · 10/8/2026
- Niagen Bioscience to Present at LD Micro 20th Annual Main EventYahoo · 10/6/2026
- Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly SlaterYahoo · 10/1/2026
- Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth?Yahoo · 9/30/2026
- Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical TrialYahoo · 9/30/2026
- Niagen Bioscience Enters Start-Up Agreement With Mass General Brigham To Plan The Largest And Most Comprehensive Clinical Trial Of Niagen To DateBenzinga · 9/30/2026
- Transcript: Niagen Bioscience Q2 2026 Earnings Conference CallBenzinga · 9/30/2026
- Niagen Bioscience: Down 68%, But Still Not Quite A BuySeekingAlpha · 9/29/2026
Insider Activity
Insider Actions →- Robert N. Fried · June 30, 2026 · Grant1.1K @ $2.71
- Ozan Pamir · June 30, 2026 · Grant4.3K @ $2.71
- Carlos Luis Lopez · June 30, 2026 · Grant2.3K @ $2.71
- Shahbazi Hamed · June 24, 2026 · Grant31.7K
- Cohen Ann · June 24, 2026 · Grant31.7K
- Ng Wang Yu Gary · June 24, 2026 · Grant31.7K
- Kristin Patrick · June 24, 2026 · Grant31.7K
- YU Wing Tak Wendy · June 24, 2026 · Grant31.7K
- Frank L. Jaksch Jr. · June 24, 2026 · Grant31.7K
- Steven D. Rubin · June 24, 2026 · Grant31.7K
- Robert N. Fried · April 24, 2026 · Option Exercise20.0K @ $2.61
Institutional Ownership
March 31, 2026
- Total shares held
- 34.90M
- Total value held
- $144.72M
- Institutional holders
- 139
- Unknown3.87M
- Unknown3.37M
- Unknown2.38M
- Unknown2.15M
- Unknown2.03M
- Unknown1.71M
- Unknown1.41M
- Unknown1.34M
- Unknown1.33M
- Unknown1.25M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
NAGE linked to new preclinical study on CD38 and NAD+ decline
A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.
NAGE linked to new preclinical study on CD38 and NAD+ decline. A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.